Polygenic risk scores (PRSs) capture the polygenic architecture of common diseases by aggregating genome-wide genetic variation into a single score that reflects individual’s disease risk, affording a new opportunity to identify downstream molecular pathways involved in disease pathogenesis. We performed an integrative analysis to characterise associations of PRSs of five cardiometabolic diseases…
Technology could be a boon for science, but raises ethical concerns
The future of the genetic data owned by 23andMe is uncertain as the company undergoes a court-supervised sale.
Kian Sadeghi was 25 years old when he decided to monetise human evolution. His company, Nucleus Genomics, charges parents $5,999 to rank their IVF embryos…
Nature – Kári Stefánsson, who last month left the Icelandic genetics company deCODE, spoke to Nature about his legacy.
Former 23andMe CEO Anne Wojcicki, through the TTAM Research Institute, will bid $305 million, topping Regeneron’s previous bid of $256 million.
Bankrupt genetic testing company 23andMe told a U.S. bankruptcy judge on Wednesday that it wants to re-open bidding on its assets, including customers’ genetic data,…
It didn’t come with a press conference or a media blitz.
Brown et al. show that bacterial sphingolipids delivered by outer membrane vesicles (OMVs) persist within mammalian immune cells and promote IL-10 secretion via the mevalonate…
Anne Wojcicki calls for fresh bankruptcy auction of genetic testing company after Regeneron won bidding
